Overview
SenesTech Q3 revenue grows 43% yr/yr but misses analyst expectations
Adjusted EBITDA loss improves
Evolve product sales grow 77% yr/yr, driving revenue growth
Outlook
Company expects accelerated growth across e-commerce sites
Company anticipates additional municipal deployments underway or planned
SenesTech intends to pursue profitable growth moving forward
Result Drivers
EVOLVE PRODUCT SALES - Evolve Rodent Birth Control products grew 77% yr/yr, now 85% of total revenue
E-COMMERCE GROWTH - E-commerce revenue increased 55% yr/yr, driven by growth in Amazon sales
MUNICIPAL DEPLOYMENT - Municipal revenue grew 139% yr/yr due to expanded deployments in NYC and Chicago
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Miss | $690,000 | $730,000 (1 Analyst) |
Q3 Net Income | Beat | -$1.30 mln | -$1.64 mln (1 Analyst) |
Q3 Income From Operations | Beat | -$1.35 mln | -$1.58 mln (1 Analyst) |
Q3 Basic EPS | -$0.28 | ||
Q3 Gross Profit | $433,000 | ||
Q3 Operating Expenses | $1.78 mln |
Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the agricultural chemicals peer group is "buy"
Wall Street's median 12-month price target for Senestech Inc is $10.00, about 66.1% above its November 7 closing price of $3.39
Press Release: ID:nPn8x94Bva
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)